Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Shares Down 4.7% – What’s Next?

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY)’s stock price fell 4.7% on Thursday . The stock traded as low as $6.75 and last traded at $6.7850. 1,251 shares were traded during trading, a decline of 61% from the average session volume of 3,221 shares. The stock had previously closed at $7.12.

Clinuvel Pharmaceuticals Stock Up 0.8%

The stock has a fifty day simple moving average of $7.79 and a 200-day simple moving average of $7.77.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.